These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34411840)

  • 21. Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review.
    Khaddour K; Singh V; Shayuk M
    BMC Cancer; 2019 May; 19(1):449. PubMed ID: 31088420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
    Feng S; Coward J; McCaffrey E; Coucher J; Kalokerinos P; O'Byrne K
    J Thorac Oncol; 2017 Nov; 12(11):1626-1635. PubMed ID: 28843363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants.
    Haraguchi Y; Nakamura K; Inoue M; Sasaki T; Minami K; Yoshimura S; Naito S
    Int Heart J; 2022; 63(1):153-158. PubMed ID: 35095064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
    Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
    In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Shionoya Y; Hirohashi Y; Takahashi H; Hashimoto M; Nishiyama K; Takakuwa Y; Nakatsugawa M; Kubo T; Kanaseki T; Tsukahara T; Torigoe T
    Anticancer Res; 2021 Jul; 41(7):3699-3706. PubMed ID: 34230169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer.
    Ofuji K; Hiramatsu K; Nosaka T; Naito T; Takahashi K; Matsuda H; Ohtani M; Imamura Y; Ishizuka T; Nakamoto Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1692-1699. PubMed ID: 34415552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
    Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
    Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
    Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
    Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
    Leighl NB; Hellmann MD; Hui R; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Lubiniecki GM; Zhang J; Piperdi B; Garon EB
    Lancet Respir Med; 2019 Apr; 7(4):347-357. PubMed ID: 30876831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review.
    Ogawa K; Kaneda H; Kawamoto T; Tani Y; Izumi M; Matsumoto Y; Sawa K; Suzumura T; Watanabe T; Mitsuoka S; Asai K; Kawaguchi T
    Invest New Drugs; 2020 Dec; 38(6):1901-1905. PubMed ID: 32399862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
    Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.
    Akagi Y; Awano N; Inomata M; Kuse N; Tone M; Yoshimura H; Jo T; Takada K; Kumasaka T; Izumo T
    Intern Med; 2020 Apr; 59(8):1075-1080. PubMed ID: 32009093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Lupus anticoagulant and ischemic strokes: about two case reports].
    Hilaire J; Noizat C; Duong MT; Delrue M; Hervé D; Stepanian A; Neuwirth M; Hadj-Ali A; Joly BS; Veyradier A; Siguret V; Béranger N
    Ann Biol Clin (Paris); 2021 Aug; 79(4):361-367. PubMed ID: 34427558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer.
    Okuzumi S; Kamata H; Emoto K; Shimizu T; Otake S; Irie H; Chubachi S; Ikemura S; Yasuda H; Fukunaga K
    Intern Med; 2023 Jul; 62(14):2113-2121. PubMed ID: 36450461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.